A groundbreaking study suggests that a straightforward blood test could detect Alzheimer's disease decades before symptoms appear, offering hope for early intervention. The research, published in The Lancet, found that identifying signature proteins associated with the condition in midlife may reveal subtle cognitive differences.
Blood Biomarkers and Cognitive Decline
Scientists analysed levels of two amyloid biomarkers and p-tau217 in blood samples from 1,350 dementia-free individuals in the US, with an average age of 61. Among them, 86 participants exhibited high levels of these biomarkers, correlating with poorer cognitive performance, accelerated verbal memory decline, and slower processing speeds over five years.
The team noted that these findings build on previous studies by showing that Alzheimer's neuropathology is present in midlife, albeit infrequently, and linked to measurable cognitive changes. They stated: "These results support the concept that Alzheimer's disease begins decades before clinical symptoms emerge and highlight the potential value of plasma biomarkers for early detection in the general population."
Implications for Prevention and Treatment
Dr Jacqui Hanley, head of research funding at Alzheimer's Research UK, emphasised the potential benefits: "Being able to identify these changes sooner could be incredibly valuable. It would open opportunities for people to take part in studies of new treatments and identify those who might benefit from disease-modifying therapies indicated for early-stage disease."
She also highlighted current challenges in the UK, where many people wait too long for a dementia diagnosis. Accurate blood tests could improve diagnosis as they are less invasive, scalable, and more accessible than PET scans or lumbar punctures.
Advanced Brain Imaging
In a separate study also published in The Lancet, a novel brain scanning technique using the tracer MK6240 detected tau protein tangles more effectively than existing methods. The study involving 682 patients across the US and Canada found MK6240 identified more than twice as many tau-positive cases in early tau regions compared to Flortaucipir, which is licensed in the UK but not routinely available on the NHS.
Future Outlook
Dementia affects approximately one million people in the UK, with Alzheimer's accounting for 60-80% of cases. The Blood Biomarker Challenge, a multi-million-pound initiative by Alzheimer's Society, Alzheimer's Research UK, and the National Institute for Health and Care Research, aims to make blood tests for dementia diagnosis available on the NHS by 2029.
Dr Hanley cautioned that further research in larger, diverse groups is needed before these approaches become routine. Nevertheless, these studies represent significant progress in detecting Alzheimer's biological changes earlier, potentially transforming clinical practice and public health policy.
